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Abstract
Primary deficiency of h-galactosidase results in GM1 gangliosidosis and Morquio B disease. Of the more than 40 disease-causing
mutations described in the Gal gene to date, about 75% are of the missense type and are scattered along the length of the gene. No single,
major common mutation has been associated with GM1 gangliosidosis. However, a Trp 273 Leu mutation has been commonly found in the
majority of patients with Morquio B disease defined genotypically to date.
We now report three new mutations in three Morquio B patients where the Trp 273 Leu mutation is absent. Two of the mutations, C1502G
(Asn 484 Lys) and A1548G (Thr 500 Ala), were found in twins (one male, one female) who display a mild form of Morquio B disease and
keratan sulfate in the urine. In their fibroblasts, residual activity was 1.9% and 2.1% of controls. On Western blots, the 84-kDa precursor and
the 64-kDa mature protein were barely detectable. The occurrence of a 45-kDa degradation product indicates that the mutated protein reached
the lysosome but was abnormally processed. In the third case, we identified only a G1363A (Gly 438 Glu) mutation (a major deletion on the
second allele has not been ruled out). This female patient too displays a very mild form of the disease with a residual activity of 5.7% of
control values. In fibroblasts from this case, the 84-kDa precursor and the 45-kDa degradation product were present, while the mature 64-kDa
form was barely detectable. The occurrence of these three mutations in the same area of the protein may define a domain involved in keratan
sulfate degradation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Morquio disease (MPS IV) occurs in two types (A and B)
due to deficiencies in two separate genes. The disorder is
characterized as a massive dysostosis multiplex with storage
of keratan sulfate but without proven primary central
nervous system involvement demonstrable either neuropa-
thologically or biochemically. Patients with type A are
generally more severely involved clinically, whereas the B
form tends to be milder with a later onset of clinical
symptoms [1,2]. Morquio A disease, the more common
form of the two, arises from mutations in the gene encoding
a 6-sulfate sulfatase that is specific for residues found in
keratan sulfate (both galactose 6-sulfate and N-acetylglucos-
amine 6-sulfate) and in chondroitin 6-sulfate (as N-acetyl-
galactosamine 6-sulfate). h-Galactosidase activity is normal
in type A patients. Morquio disease, type B (MPS IVB)
arises from deficiency in h-galactosidase where the activity
of the 6-sulfate sulfatase is normal. A deficiency in the same
h-galactosidase arising from the same Gal gene is also the
primary defect in GM1 gangliosidosis. The latter is clin-
ically heterogeneous and is characterized as a neuronal lipid
storage disease, with GM1 ganglioside as the primary
storage product in central nervous system neurons (see
Ref. [1] for a recent review of this topic).
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The h-galactosidase gene, located on chromosome
3p21.33 [3–5] is 62.5 kb in length and composed of 16
exons [6,7]. Two related proteins arise by alternative splic-
ing of the primary h-galactosidase transcript. The most
abundant product is lysosomal h-galactosidase that we have
shown is catalytically active in its precursor form. The
second protein, originally called the h-galactosidase-like
protein, does not display h-galactosidase activity and has
been characterized by us as the elastin binding protein
(EBP) of the elastin binding receptor. It arises by alternative
splicing whereby the sequence encoded by exons 3, 4 and 6
is missing, a frameshift occurs in exon 5 (which encodes a
unique 32-amino-acid sequence) [6] and the reading frame
is restored at the start of exon 7. Except for this frame-
shifted unique sequence, the primary structure of the EBP is
identical to h-galactosidase. However, the latter is localized
to the cell surface but not to lysosomes [6,8].
Mutations are spread throughout the gene, 70% of which
occur simultaneously in both h-galactosidase and the EBP.
Most are of the missense type and give rise to GM1
gangliosidosis. Most patients with GM1 gangliosidosis
are heteroallelic with different mutations on each parental
chromosome and missense mutations affecting some
codons (such as those affecting Arg 59, Arg 201, Arg
208, Pro 263, Arg 482) have been noted more frequently
than others. In contrast, a major common mutation, Trp 273
Leu, has been found in the majority of the 17 Morquio B
patients that have been defined [9,10] to date. It is note-
worthy that no patient with one copy of the Trp 273 Leu
mutation has presented with GM1 gangliosidosis; all such
patients have the clinical and biochemical phenotype of
Morquio B disease.
h-Galactosidase cleaves substrates by formation of a
galactosylated-amino acid intermediate (the catalytic nucle-
ophile), with subsequent release of the galactose and reten-
tion of h-configuration. This mechanism predicts that at least
two acidic residues are involved in the catalytic mechanism.
We identified the galactosylated residue as Glu 268 [11] and
our recent work has identified Asp 332 as a candidate for the
second acidic residue in the catalytic mechanism [12].
Because Trp 273 Leu has been the only mutation strictly
associated with Morquio B disease to date, it has been
postulated to play an essential role in the hydrolysis of
keratan sulfate. However, to date, there have been no studies
directly examining this question. It has also been proposed
that the Trp 273 Leu mutation affects the ability of h-
galactosidase to join a lysosomal complex also containing
cathepsin A, neuraminidase and GalNAc-6-sulfate sulfatase,
the formation and function of which is poorly understood.
Thus, the role of Trp 273 in complex binding and hydrolysis
of natural substrates, particularly the keratan sulfates, is ill
defined.
In the present work, we describe new mutations, Asn 484
Lys and Thr 500 Ala in a set of fraternal twins and Gly 438
Glu in a third unrelated patient, all of whom display the
clinical and biochemical features of Morquio B disease. The
Trp 273 Leu mutation is absent from these patients. The
present data have appeared in abstract form [13].
2. Materials and methods
2.1. Clinical findings
The patients included in this study satisfy the criteria for
Morquio disease; namely, systemic bone disease without
primary involvement of the central nervous system (defined
as retarded developmental milestones, retarded intellectual
development, presence of spasticity and seizures). Family 1.
The first of the twins presented at age 9 years with an
abnormal gait and increased fatigability. On examination,
he was not dysmorphic, there was no hepatosplenomegaly,
and the neurological exam was normal. Some hip weakness
was noted. X-rays of the spine revealed platyspondyly with
vertebral beaking typical of MPS IV. Keratan sulfate was
isolated from his urine at this time. Residual leukocyte h-
galactosidase activity was < 2.5% of the normal level (in all
aspects of this study activity was assayed with the fluori-
metric 4-methylumbelliferyl-h-D-galactopyranoside sub-
strate as previously described [14]). By age 11 years,
odontoid dysplasia, thoracolumbar scoliosis, and genu val-
gum typical of the disease were evident. M.S., his twin, was
essentially normal at age 9.5 years. Keratan sulfate was
isolated from her urine also and again residual leukocyte h-
galactosidase activity was < 2.5% of the normal level. Amild
dorsal scoliosis was noted at age 11 years. At age 18 years,
her neurological status was within normal limits, she had an
unsteady gait but remained ambulatory, and was otherwise
healthy. Their early developmental history was uninforma-
tive and the parents (Portuguese) are unrelated. Both patients
now in their late-20s are educated both having successfully
completed post-secondary education, their neurological sta-
tus remains within normal limits, but their skeletal abnormal-
ities seriously impair their ambulatory capabilities.
Family 2. This female was diagnosed at the age of 8
years by the presence of keratan sulfate in the urine and a
deficiency of leukocyte h-galactosidase ( < 1% of the nor-
mal value) was noted. At 18.5 years, she was short (147.5
cm), had a mild dorsal scoliosis, denied pain in the joints or
back, and she had mild limitation of movement of neck,
spine, hips and shoulders. Her neurological exam was
unremarkable, she was judged to be somewhat dull, and
on psychological assessment, her IQ was judged to be
borderline normal. Corneal clouding was noted at this time,
and the cardiovascular system was normal. This patient
married and is now in her early 30s but she and her parents
now have been lost to follow-up.
2.2. Fibroblast culture
Fibroblast strains were established for diagnostic studies
that were subject to informed consent. Cells from a case of
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Morquio disease, type B (GM01602; mutations TG817/
8CT; Trp 273 Leu and G1445A; Arg 482 His), and GM1
gangliosidosis (GM05652A; homozygous for mutation
C1101T; Arg 351 ter) were from the NIGMS Human
Genetic Mutant Cell Repository. In general, skin fibroblasts
were grown in a-MEM with penicillin (100 U/ml) and
streptomycin (100 mg/ml), supplemented with 10% fetal
calf serum (FCS) at 37 jC in 5% CO2 atmosphere until
confluent. All cell cultures used in this work were negative
for the presence of mycoplasma contamination, as analysed
by a PCR-based method. In the leupeptin experiments,
cells were grown in a-MEM medium (in the presence or
absence of 20 AM leupeptin) with 10% of FBS at 37 jC in
5% CO2.
2.3. Isolation of genomic DNA
Genomic DNAwas isolated from harvested cultured skin
fibroblasts suspended in lysis buffer (100 mM NaCl, 10 mM
Tris–Cl pH 8, 25 mM EDTA pH 8, 0.5% SDS, and 0.1 mg/
ml proteinase K) by freeze/thawing (10 ) the cells in a dry
ice/ethanol bath. An equal volume of phenol/chloroform was
then added, and DNAwas precipitated by adding 1/2 volume
of 7.5 M ammonium acetate and 2 volumes of 100% ethanol.
The DNA pellet was rinsed with 70% ethanol and dissolved
in 10 mM Tris pH 8, 0.1 mM EDTA pH 8 (TE buffer).
2.4. PCR and restriction enzyme analysis
Exons 2–16 were amplified from 500 ng of patient or
normal genomic DNA. The primers used to amplify the
appropriate exons of the h-galactosidase gene and those used
for site-directed mutagenesis are based on the published
intron/exon junction sequences [7]. DNA amplification reac-
tions were performed in 100 Al total volume containing: 100
ng of each primer, 10 units of Taq polymerase (Promega), 0.5
mM each of dCTP, dGTP, dTTP, and dATP, in 10 mM Tris–
HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2. The reaction
conditions were 1 min at 94 jC (denaturation), 1 min 10 s at
56 jC (annealing), and 1 min at 72 jC (extension) for 30
cycles using the RoboCycler 40 (Stratagene) thermal cycler.
PCR products were run on a 1% agarose gel to check for
insertions or deletions before SSCP analysis was performed.
To detect the presence of the Trp 273 Leu mutation com-
monly found in Morquio B disease, we adapted the assay
described by Oshima et al. [15]. The upstream primer
sequence was 5V-CAATTCTGAATTCTATACAGGC-3Vand
the downstream primer was 5V-CATTCTAGCATAAGTTC-
TACAG-3V. The PCR product (285 bp) containing the mis-
paired A nucleotide in the upstream primer coupled with the
TG817/818CT (Trp 273 Leu) mutation creates a Stu1
restriction site where the product is cleaved into 264-
and 21-bp fragments. The positive control for this assay
were cells from the known case of Morquio disease, type
B (from the NIGMS Human Genetic Mutant Cell Reposi-
tory—GM01602). This cell line was confirmed to be hetero-
zygous for the TG817/818CT (Trp 273 Leu) mutation and for
Arg 482 His, a mutation described in patients with GM1
gangliosidosis [16]. To examine the possibility that the
mutations found were the result of polymorphic changes, the
following primer pairs were used. For exon 13, 5VTAGTGA-
TGTATTTTTCTTAAATCC-3Vand 5V-GGACAAAACGCA-
CAGTTCAG, the 183-bp PCR product contains two Hinf1
cut sites (generating 116, 40, and 27 bp pieces), one of which
is lost in the presence of the G1363A (Gly 484 Glu) mutation
(156 bp and 27 bp pieces); for exon 14, the upstream primer
5V-GTAGAGAACATGGGACGTGTTAA-3Vwas modified (T
underlined) to create a new Hpa1 site. The downstream
primer was 5V-TTAAACCTTAGTCTTGACAGTG-3V. In the
presence of the C1502G (Asn 484 Lys) mutation, the new
Hpa1 site is lost. For exon 15, the upstream and downstream
primers were 5V-CAGCTCACTGTGCTCTGTT-3Vand 5V-
GAATTCAAACCCTTCCCATGA-3V, respectively. In the
presence of the A1548G (Thr 500 Ala) mutation, the unique
Hinf1site is lost.
2.5. SSCP analysis
SSCP analysis was performed at room temperature and at
4 jC with 6% polyacrylamide gels in 0.5TBE running
buffer containing 5% glycerol (40 W) as described by Refs.
[17,18]. The gels fixed in 50% methanol and 10% acetic
acid solution for 1 h were washed three times in distilled
water for 15 min and then stained in a solution containing
equal volumes of 0.5 M sodium carbonate and 10 mM silver
nitrate–25 mM ammonium nitrate–3.5 mM tungstosilicic
acid–0.8% formalin for 10–30 min. The reaction was
stopped by the addition of 10% acetic acid.
2.6. DNA sequencing
Direct sequencing of PCR products in both directions
followed the Amersham 33P-thermosequenase cycle se-
quencing protocol.
2.7. Western blot analysis
Cells were harvested by scraping in phosphate-buffered
saline and lysed by sonication as described earlier. Thirty
micrograms of fibroblast protein was analysed using SDS-
PAGE. Samples were reduced by boiling for 5 min in 62.5
mM Tris, 3% SDS, 10 mM DTT, and were loaded onto an
8% Bio-Rad Mini Gel SDS-polyacrylamide system as
described earlier [12]. Proteins were transferred overnight
to nitrocellulose, and the Western blot was probed using a
1:1500 dilution of the polyclonal rabbit IgG (P-Gal) raised
against purified human h-galactosidase precursor. This
multiepitopic antibody reacts with all known forms of the
wild-type and mutant protein including their degradation
products [12,19]. Immunoblots were developed using the
enhanced chemiluminescence system (ECL-Western Blot,
Amersham).
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2.8. Immunolocalization of b-galactosidase in intracellular
compartments
Histochemical staining was by incubation of fixed per-
meabilized cells with indolyl-h-galactoside [20]. Cells were
grown in a-MEM medium (in the presence or absence of 20
AM leupeptin) with 10% of FBS at 37 jC in 5% CO2 on
glass cover slips, and after 48 h, the cells were fixed and
gently permeabilized with 100% cold methanol at  20 jC
for 30 min. The fixed cells were then washed in phosphate-
buffered saline, blocked with 1% bovine serum albumin,
and incubated for 1 h with rabbit IgG raised against purified
human h-galactosidase precursor as above (diluted 1:200).
The secondary antibody, a green fluorescein-labeled goat-
anti-rabbit IgG F(abV)2, diluted 1:100, was then added for 1
h, either alone or in combination with a 1:10,000 dilution of
propidium iodide, which in addition to nuclear DNA also
stains cytoplasmic RNA, and RNA bound to the rough ER
thereby marking the position of the ER with the red
fluorescence. The cells were then washed three times with
phosphate-buffered saline and mounted with elvanol [21]. In
control cultures, the preimmune rabbit IgG was substituted
for the primary antibody.
3. Results
3.1. Identification of the mutations
Direct sequencing of PCR products was used to identify
mutations in exons 2–16 using intron/exon primers as
described by Morreau et al. [7]. Both patients in Family 1
were found to be heterozygous for two mutations, a
C1502!G transversion in exon 14 which converts Asn
484 to Lys (Fig. 1a), and an A1548!G substitution in exon
15 which converts Thr 500 to Ala (Fig. 1b). The patient in
Family 2 was homozygous for a G1363!A substitution
which converts Gly 438 to Glu in exon 13 (Fig. 1c). We did
not detect the nucleotide changes noted in the Morquio
patients defined in this study using genomic DNA samples
from 30 normal fibroblast lines supporting the assignment of
these mutations as disease-causing and not naturally occur-
ring polymorphisms. The Trp 273 Leu mutation commonly
found in patients with Morquio B disease was confirmed in
the cell repository Morquio B line used as the positive
control as was the Arg 482 His mutation. The Trp 273 Leu
mutation was not present in any of the current patients.
Fig. 1. Identification of mutations in Families 1 and 2. Genomic DNAwas
isolated as described. One mutation was detected in each of exon 14 and 15
in Family 1 and in exon 13 in Family 2. Genomic fragments were amplified
from 500 ng of patient or normal DNA using primers based on intronic/
exonic sequences and using the amplification conditions as described in the
Materials and Methods. Direct sequencing of PCR products in both
directions followed the Amersham 33P-thermosequenase cycle sequencing
protocol. In Family 1, we noted in exon 14 a C1502G transversion which
changed Asn 484 to Lys (Panel a), and an A1548G substitution converting
Thr 500 to Ala (Panel b) in exon 15. In Family 2, the only mutation noted
was a G1363A substitution converting Gly 438 to Glu (Panel c) in exon
13.
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3.2. Level of b-galactosidase protein
The total h-galactosidase activity in fibroblast extracts
from our Morquio B patients was 2.1% and 1.88%, respec-
tively, for the twins in Family 1, and 5.67% in the patient
from Family 2 (Table 1). This compares favourably to the
values obtained for the positive Morquio B control from the
cell repository (1.2%). All of these residual activities are
higher than the extremely low level of activity in the GM1
gangliosidosis cells ( < 0.5% of the control) included in the
study and are consistent with other known cases [12]. To
assess the impact of these mutations on the level of h-
galactosidase protein in these cells, we used our well-
characterized rabbit polyclonal antibody in Western blot
analyses. We detected very small but comparable to normal
amounts of the 84-kDa precursor in cells from the Family 1
patients (Fig. 2, lanes 1 and 6), and the case from the cell
repository (Fig. 2, lane 3), while in the third patient (from
Family 2), the precursor was more abundant (Fig. 2, lane 2).
The processed, mature 64-kDa polypeptide, the most abun-
dant form of the enzyme, was easily detected as expected in
normal cells. The mature protein was decreased in the Family
1 fibroblasts (Fig. 2, lanes 1 and 6) to the levels seen in the
GM1 gangliosidosis cells (Fig. 2, lane 5), but was found at
a higher level in fibroblasts from Family 2 (Fig. 2, lane 2).
On the other hand, fibroblasts from the positive Morquio B
control displayed significant amounts of the 64-kDa mature
protein (Fig. 2, lane 3). It is noteworthy that in all fibroblasts
except those from the patient with the stop codon mutation
(Fig. 2, lane 5), prominent degradation products in the range
of 45 kDa were detectable. However, the relative abundance
of these forms was not constant. For example, as in the
normal cell line, Family 1 and 2 cells appeared to have a
single major degradation product compared to at least two
for the cell repository case and three major bands in one of
the GM1 gangliosidosis cases. The relative abundance of all
forms of the protein in the Morquio B cases was substantially
higher than that found in the case of GM1 gangliosidosis
used as a control but was still lower than that noted in the
control cell line. Maturation of the precursor to the mature
protein and formation of these degradation products arise
exclusively from lysosomal digestion since as we have
previously shown in I-cell fibroblasts, where the precursors
are not localized into lysosomes due to the absence of the
mannose 6-phosphate targeting signal, that the enzyme is not
Table 1
Mutations correlated with enzyme activity and Western blots
Cell line Specific activitya Western blot result
mutations h-Gal Hex
Family 1
sibling 1 Asn 484 Lys
Thr 500 Ala
30 18,220 some precursor,
little mature h-gal,
degradation products
sibling 2 Asn 484 Lys
Thr 500 Ala
27 13,602 some precursor,
little mature h-gal,
degradation products
Family 2
Patient 1 Gly 4328 Glu
homozygous
81 22,248 abundant precursor,
little mature h-gal,
degradation products
Cell repository
Trp 273 Leu
Arg 482 His
17 11,772 some precursor,
some mature h-gal,
degradation products
GM1 gangliosidosis
Arg351STOP 3 21,690 little precursor,
little mature h-gal,
no degradation products
Normal
none known 1429 17,419 some precursor,
mature h-gal,
some degradation
products
a Specific activity is nanomoles per hour per milligram of protein.
Fig. 2. Western blot of fibroblast lysates from Morquio B and GM1-
gangliosidosis patients. Thirty micrograms of total cellular protein was
analysed by SDS-PAGE and probed using our well-characterized antibody
that cross-reacts with the 84-kDa precursor and the 64-kDa mature forms of
h-galactosidase. Lane 1 is Morquio B, sibling 1 of Family 1; Lane 2, is the
case from Family 2; Lane 3 is a Morquio B cell line (GM01602) from the
NIMCGS repository; Lane 4 is a normal control; Lane 5 is a case of GM1
gangliosidosis, homozygous for an Arg351STOP mutation; Lane 6 is
sibling 2 of Family 1; Lane 7 corresponds to wild-type h-galactosidase
expressed by CHO cells, as described earlier [14] and demonstrates the
location of the 84-kDa precursor and the 64-kDa processed mature form of
the enzyme.
Fig. 3. Western blot of lysates from Morquio B patients incubated in the
presence of leupeptin. Thirty micrograms of total cellular protein was
analysed by SDS-PAGE and probed using our well-characterized antibody
that cross-reacts with the 84-kDa precursor, the 64-kDa mature form and the
major degradation product of h-galactosidase at 45 kDa. Lane 1 is Morquio
B, sibling 2 of Family 1; Lanes 2 and 3 is Morquio B, Family 2; Lanes 4
and 5 is Morquio B cell line (GM01602) from the NIMCGS repository;
Lanes 6 and 7 is a normal control. Lanes 1, 3, 5, and 7 are lysates from cells
grown in the presence of leupeptin for 48 h; lanes 2, 4, 6 are from cells
grown in the absence of leupeptin.
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processed but rather degraded [19]. These findings are
summarized in Table 1. Because it could be argued that the
mutant proteins in the Morquio B lines reached the lyso-
somes in normal abundance but were quickly degraded, we
examined the level of h-galactosidase proteins in cells
incubated in the presence of leupeptin (Fig. 3). We previ-
ously showed in galactosialidosis fibroblasts, where the h-
galactosidase deficiency is a secondary manifestation of the
primary deficiency in cathepsin A/protective protein, incu-
bating the fibroblasts in the presence of leupeptin restored h-
galactosidase to normal levels but did not affect processing
to the mature enzyme [19]. In this instance, exposure of
Morquio B cells to leupeptin did not effect a rise in h-
galactosidase activity regardless of the nature of the muta-
tions (Table 2). No substantial change in the level of h-
galactosidase proteins (precursor, mature or degraded forms)
were noted in the Morquio B lines with the Asn 484 Lys/Thr
500 Ala or the Gly 438 Glu mutations in the presence of
leupeptin. In contrast, in the control lines used (in both the
Trp 273 Leu/Arg 482 His Morquio B line and in the normal),
leupeptin treatment resulted in a net increase of h-galacto-
sidase proteins. Since leupeptin did not result in a rise of the
enzyme protein in the presence of the Asn 484 Lys/Thr 500
Ala or the Gly 438 Glu mutations, it implies that the mutated
protein does not reach the lysosome but rather is degraded in
a pre-lysosomal compartment. In support of this, we under-
took immunofluorescence localization studies. Here, h-gal-
actosidase protein was found primarily in the perinuclear
area (i.e. the endoplasmic reticulum) with some immunor-
eactivity dispersed in organelles distant from the nucleus
(data not shown).
4. Discussion
Novel missense mutations (Thr 500 Ala, Asn 484 Lys,
and Gly 438 Glu) have been found in three patients in two
families who display a mild form of Morquio B disease
(primary h-galactosidase deficiency with keratan sulfate
storage). Subsequent to our conference report [13], Paschke
et al. [10] found the same A1532C, Thr 500 Ala mutation in
another mild patient diagnosed at the age of 24 years, but
they did not examine the impact on the level of cross-
reacting material. In the presence of the Thr 500 Ala and
Asn 484 Lys mutations, minimal amounts of precursor (84
kDa) and mature (64 kDa) forms of h-galactosidase were
detected, the most abundant form of h-galactosidase protein
being a 45-kDa degradation product. With the Gly 438 Glu
mutation, both the precursor and the 45-kDa degradation
product were noted but again only minimal amounts of the
mature form of the enzyme were detected. Incubation of
these cells with leupeptin, a potent thiol protease inhibitor,
did not affect the level of residual h-galactosidase protein nor
did it have any effect on the level of residual activity. On the
other hand, with leupeptin treatment, there was a noticeable
increase in the level of h-galactosidase precursor protein in
control cells and in cells from the Morquio B patient
heterozygous for Trp 273 Leu and Arg 482 His mutations,
but no change in enzyme activity was observed in the latter.
Consistent with this are our initial unpublished findings that
show the mutant protein containing the Trp 273 Leu muta-
tion to be catalytically defective at least with synthetic
substrates. The failure to alter the level of h-galactosidase
protein in the presence of leupeptin suggests that the proteins
bearing the Thr 500 Ala, Asn 484 Lys, and Gly 438 Glu
mutations do not reach the lysosome and are likely degraded
in the endoplasmic reticulum, as we have previously shown
for missense mutations causing GM1 gangliosidosis [12].
In normal cells, upon arrival in the endosomal–lysosomal
compartment, h-galactosidase associates with Neuramini-
dase, protective protein (cathepsin A), and N-acetylglucos-
amine 6-sulfate sulfatase [22] to form a stable complex
responsible for the hydrolysis of GM1 ganglioside and
keratan sulfate. Complex formation is absolutely essential
for h-galactosidase stabilization and for its normal posttrans-
lational processing from the precursor to its mature form.
Pshezhetsky and Potier [22] demonstrated that the complex
also contained N-acetylgalactosamine 6-sulfate sulfatase, the
enzyme deficient in Morquio disease, type A, and that its
activity was reduced in galactosialidosis. This was correlated
with elevated levels of keratan sulfate in the urine of
galactosialidosis patients. These data indicate that digestion
of keratan sulfate is intimately associated with and dependent
upon both complex formation and correct processing of the
enzyme. In earlier studies using I-cell fibroblasts, we showed
that h-galactosidase precursor is degraded to a low molecular
weight fragment (about 18 kDa), but no larger intermediate
forms were detected. This non-lysosomal proteolysis of h-
galactosidase arises due to its mislocalization reflecting the
enzyme deficiency in I-cell disease. Because the mutations
described here resulted in formation of significant amounts
of the 45-kDa degradation products, it is clear that a
substantial amount of the mutant enzyme reached the lyso-
some. However, little productive processing of the precursor
to the mature 67-kDa form was noted suggesting that these
mutations likely affect the protein’s ability to associate
correctly with the lysosomal complex, a crucial step for the
enzyme’s maturation and for keratan sulfate digestion. On the
other hand, in the cell line with the Trp 273 Leu mutation,
Table 2
The effect of leupeptin on h-galactosidase in fibroblasts
Specific activity (nmol/h/mg of protein)
No leupeptin With leupeptin
Control 681.3 994.4
Morquio B, Family 1, Case 1 8.9 7.0
Morquio B, Family 2 19.9 18.1
Morquio B, cell repository 7.8 7.8
GM1 gangliosidosis 0.0 0.0
Cultured skin fibroblasts were incubated for 48 h in the presence of 10 mM
leupeptin, after which the cultures were harvested, and processed as
described.
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measurable productive processing of the precursor to the
mature protein occurred. These differences suggest that
keratan sulfate catalysis is impaired in the presence of the
Thr 500 Ala, Asn 484 Lys and Gly 438 Glu mutations
because formation of the complex is abnormal, whereas with
the Trp 273 Leu mutation, complex formation occurs, but the
enzymemay be catalytically defective with respect to keratan
sulfate degradation. Therefore, the occurrence of these new
mutations in an area bounded by Gly 438–Thr 500 may
define a region of h-galactosidase that is pivotal in its binding
to the complex either alone or in conjunction with keratan
sulfate binding and further work is required to examine this.
We have documented that the alternatively spliced form of
h-galactosidase is identical to the 67-kDa EBP, the major
function of which is to associate with a cell surface elastin
binding receptor and to assist in the delivery of tropoelastin
to form the extracellular matrix [8,23,24]. The elastin bind-
ing receptor is composed of EBP, and two other proteins,
which we have shown to be neuraminidase, and protective
protein (cathepsin A). Release of newly secreted tropoelastin
molecules from the association with EBP occurs upon
interaction between it and galactosugar moieties protruding
from the carbohydrate chains of glycoproteins thus facilitat-
ing formation of the microfibrillar scaffold of elastic fibers.
In parallel studies on fibroblasts from the Morquio B patients
used in the present work and from patients with GM1
gangliosidosis, we have found that cell lines from patients
with Morquio disease type B have decreased capacity to
assemble elastic fibers, whereas most GM1 gangliosidosis do
not have this impairment [21]. In addition, we have noted
that cells from patients with galactosialidosis and sialidosis
also do not assemble elastic fibers [21]. These data are in
accord with the recent findings that newly synthesized PPCA
and neuraminidase associate in the ER are secreted together
and reside in the plasma membrane [25,26] and are in
agreement with our earlier data [23,24]. The sequences
where the three novel missense mutations described here
occur are identical between h-galactosidase and its alterna-
tively spliced EBP form. The full impact of these mutations
on the pathophysiology of Morquio B disease will only be
realized when the respective mutations have been introduced
into EBP and their impact on its function directly determined.
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